The Faculty of Medicine at the University of Hong Kong announced on the 10th that their research team has developed an oral drug called arsenic trioxide (commonly known as "arsenic"), which can be used to treat acute promyelocytic leukemia with a survival rate of 97% for patients. According to researchers from the Faculty of Medicine at the University of Hong Kong, clinical studies have shown that oral arsenic has high efficacy and safety in treating acute promyelocytic leukemia. The overall survival rate of patients is 97%, and it can significantly reduce side effects and treatment burden. The research team is currently testing a fully oral treatment regimen in Hong Kong, consisting of medicinal oral arsenic, all trans retinoic acid, and ascorbic acid, adjusted according to the risk of different acute promyelocytic leukemia patients. The chief researcher of this study, Dr. Qiao Xiali, Associate Professor of Clinical Medicine at the School of Clinical Medicine of the University of Hong Kong, stated that this all oral treatment plan can provide drug therapy for acute promyelocytic leukemia patients with different risk levels in a specialized outpatient environment. In addition, the treatment regimen of oral arsenic can significantly reduce the use of chemotherapy. (New Society)